Aurobindo Pharma Ltd

As of June 30, 2026, Aurobindo Pharma Ltd carries a market capitalization of 906.74B, placing it among publicly traded companies globally. Its enterprise value stands at 906.74B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aurobindo Pharma Ltd's next confirmed earnings release is scheduled for November 14, 2026.

As of June 30, 2026, Aurobindo Pharma Ltd has 575.40M shares outstanding.

As of June 30, 2026, Aurobindo Pharma Ltd trades at a trailing price-to-earnings ratio of 24.78.

As of June 30, 2026, Aurobindo Pharma Ltd trades at an EV/EBITDA multiple of 13.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 906.74B versus a market cap of 906.74B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.86M in revenue per employee across its workforce of 43,602.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Aurobindo Pharma Ltd recorded 16.64B in income tax expense. That works out to an effective tax rate of 31.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 53.51B, leaving 36.89B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Aurobindo Pharma Ltd's stock has gained approximately 42.80% over the past 52 weeks. The 50-day moving average sits at 1,661.34, while the 200-day moving average is 1,446.35.

Over the twelve months ended June 30, 2026, Aurobindo Pharma Ltd generated 342.54B in revenue and converted that into 36.89B in net income, yielding earnings per share of 63.55. EBITDA reached 69.53B, while operating income came in at 52.23B.

Over the twelve months ended June 30, 2026, Aurobindo Pharma Ltd posted a gross margin of 59.78, reflecting its pricing power and cost economics. The operating margin of 15.25 and net profit margin of 10.77 provide insight into operational efficiency.

Aurobindo Pharma Ltd's most recent stock split took place on July 20, 2015 with a 1:2 split ratio.